Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 1
2007 3
2009 1
2010 8
2011 4
2012 13
2013 17
2014 17
2015 18
2016 28
2017 26
2018 19
2019 23
2020 28
2021 59
2022 55
2023 42
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

333 results

Results by year

Filters applied: . Clear all
Page 1
Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study.
Jia S, Yin Z, Pan H, Wang F, Liu X, Wang Q, Zhang L, Tang J, Yang H, Du J, Wang Z, Jin P, Peng Z, Tang R, Kang G, Wang X, Li S, Wang W, Li J, Shen H, Zhu F. Jia S, et al. Among authors: li j. Emerg Microbes Infect. 2024 Dec;13(1):2332660. doi: 10.1080/22221751.2024.2332660. Epub 2024 Apr 28. Emerg Microbes Infect. 2024. PMID: 38678636 Free PMC article.
ISGylation by HERCs facilitates STING activation.
Qin Y, Wang M, Meng X, Wang M, Jiang H, Gao Y, Li J, Zhao C, Han C, Zhao W, Zheng X. Qin Y, et al. Among authors: li j. Cell Rep. 2024 Apr 21;43(5):114135. doi: 10.1016/j.celrep.2024.114135. Online ahead of print. Cell Rep. 2024. PMID: 38652662 Free article.
Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies.
Balgos A, Hannawi S, Chen WL, Abuquta A, Safeldin L, Hassan A, Alamadi A, Tirador L, Jaen AM, Villalobos RE, Mo C, Yue ZJ, Ma Y, Wang QS, Wen RD, Yao Z, Yu JP, Yao WR, Zhang JH, Hong KX, Liu Y, Li JX. Balgos A, et al. Expert Rev Vaccines. 2024 Jan-Dec;23(1):419-431. doi: 10.1080/14760584.2024.2334423. Epub 2024 Apr 2. Expert Rev Vaccines. 2024. PMID: 38529685 Free article. Clinical Trial.
333 results